Introduction
Since the results of the TARGIT-A trial were published (1) , partial irradiation of the breast with TARGIT-IORT using an intraoperative dose of 20 Gray (Gy) with a 50kV X-Ray source is being increasingly used within a risk adapted approach to replace whole breast irradiation in selected patients (http://goo.gl/kGFSJx). It is included in several national guidelines and has been approved and reimbursed in the Australian national health system. The concept of reducing the extent of radiation is not unopposed, although the emotionality of this discussion may well be compared to oppositions against breast conservation when it was first proposed as an alternative to mastectomy.
However, use of TARGIT-IORT as an intraoperative boost has been an option for much longer. The first study for the use of this technique as a replacement for the external boost demonstrated a local recurrence rate of 1.76 % after 5 years rather than the expected 4.3 % for the external boost, a local recurrence rate that could subsequently be reproduced in other cohorts (2) (3) . Even when used in high-risk patient cohorts such as patients with triple negative (TN) breast cancer in a trial using electrons as an intraoperative radiation (IOERT) the intraoperative boost resulted in a favourable outcome (4) . However, although the use of intraoperative radiotherapy as an intraoperative boost is widely used in primary surgery, its use in patients who undergo breast conserving operations is still a not a standard.
In the last decade neoadjuvant therapy has become a standard of care not only for inoperable or locally advanced cases but also for smaller operable tumours. Although neoadjuvant chemotherapy has been proven to increase the rate of breast conserving surgeries this is commonly not regarded as main rationale for use. Instead, it is commonly regarded as an option for all patients where systemic therapy is definitely indicated at the time of diagnosis with the goal of improving disease free survival (DFS) and overall survival (OS) (5) by carrying the potential for response-guided treatment since allowing an in-vivo observation of chemotherapy sensitivity in an individual tumour. Regimens used in the neoadjuvant setting in clinical practice are usually extrapolated from the adjuvant therapy.
Use of chemotherapy in HER2 positive and TN breast cancer is common clinical practice, but high-risk HR positive, HER2 negative patients with tumours showing a high proliferation rate, high tumour burden in breast and/or axilla or further risk factors such as grade 3 or high risk classification based on a multigene assay may benefit from cytotoxic therapy and are therefore also candidates for neoadjuvant chemotherapy. A lack of expression of oestrogen and progesterone receptor with or without overexpression of HER2 in combination with high proliferative activity indicated by grade 3 according to Elston and Ellis, high expression of Ki67 or genomic grade index are the main predictors for response to neoadjuvant therapy (6) (7) .
Achieving a pathological complete response (pCR) is considered to indicate a better prognosis especially for ER negative tumours (8) . These considerations have led to an increasing number of patients receiving neoadjuvant systemic therapy before breast conserving therapy.
Patients receiving neoadjuvant systemic therapy have a higher risk for local and distant recurrence because of their tumour biology. One might expect that these high-risk patients might benefit from the better disease control achieved by intraoperative radiotherapy as a boost as mentioned above. Electrons as an intraoperative boost (IOERT) after primary systemic therapy were found to achieve excellent local control rates and a trend for superiority compared to a cohort receiving an external boost (9) . First data for the use of IORT with the 50kV X-ray source in this indication have been presented by our study group in 2015 showing a favourable outcome in a one arm observational design (10) .
A previous study from our group including 116 patients showed a beneficial effect of TARGIT-IORT on OS but not DFS after neoadjuvant chemotherapy compared to an external boost (11) . Although these data have to be interpreted with caution because of the retrospective design of the study and the comparatively small number of patients this can be seen as a sign for non-inferiority of TARGIT-IORT as an intraoperative boost. In this study we present an analysis of the subset of patients with TN and HER2 positive tumours from this cohort in order to test the hypothesis of non-inferiority of TARGIT-IORT among in the subset of patients with high-risk breast cancer. 
Method

Patients
Results
Median follow-up was 49 months for both cohorts. No subject was lost to follow-up. Characteristics of the study population are shown in tables 1 and 2. Apart from tumour size before start of neoadjuvant chemotherapy in the TN group there were no significant differences between the two cohorts. The toxicity data for the cohort from which the experimental group receiving TARGIT-IORT as a boost after neoadjuvant chemotherapy was extracted have been reported before and were comparable with the average postoperative morbidity after breast conserving surgery in our institution (8) .
5-year Kaplan-Meier estimates of OS showed no significant difference among HER2 positive tumors: on the cohort of TARGIT and EBRT 0 vs. 1 event occurred (100% vs. 91.7%, log rank p = 0.22). The same was seen for DFS with 2 vs. 4 events (83.3% vs. 77.0%, log rank p=0.38). The results for TN cases were similar: OS rates were 87.5 vs. 74.1% (2 vs. 3 events, log rank p=0.488) and DFS rates were 87.5 vs.
60.0% (2 vs. 4 events, log rank p=0.22). Kaplan-Meier curves can be found in figures 1 to 4. 
Discussion
In this non-randomized retrospective cohort analysis we compared intraoperative tumour bed boost with a 50kV X-ray device with an external boost among patients undergoing breast conserving surgery after neoadjuvant chemotherapy including only the two high-risk groups of patients with TN and HER2 positive tumours. All patients received external beam whole breast irradiation. Disease control rates found in our series were similar. Whereas in the whole cohort reported before OS was significantly better in the TARGIT-IORT cohort (11) , in this analysis of patients representing an even higher risk in the high-risk group of patients after neoadjuvant chemotherapy neither DFS nor OS differed significantly between patients receiving an external boost and patients receiving TARGIT-IORT although trends favoured TARGIT-IORT.
Initial reports about patients treated with TARGIT-IORT as an intraoperative boost during breast conserving operations suggested that it might achieve superior local control (3) . This approach has become a standard in some centers, particularly in Germany and the USA. TARGIT-IORT as the only radiotherapy in the course of breast conserving surgery has been found to have local recurrence rates that are not significantly different from external whole breast irradiation in selected patients in a risk adapted approach in the TARGIT A trial (1) . Regarding the question of local side effects the rate of breast fibrosis found with TARGIT-IORT is within the range seen with EBRT alone (12) . In previous studies we found that adapting this approach among patients who were undergoing breast conserving therapy after neoadjuvant systemic therapy does not compromise cosmetic outcome (13) ; it also does not interfere with pathological evaluation of the margins and does not alter re-excision rates (14) .
Patients who need to be treated with neoadjuvant therapy are generally at high risk of local and distant relapse and of death from breast cancer (15, 16) . A retrospective analysis using a different technique of intraoperative radiotherapy -Intraoperative Electron radiotherapy (IOERT) compared 83 patients receiving IOERT after neoadjuvant therapy with a rather small group of 26 patients receiving conventional EBRT boost found a trend for superiority for IOERT (9) .
The rationale for our investigation was based on our findings regarding the whole cohort. In this analysis patients receiving their boost as TARGIT-IORT had a statistically significant better overall survival (11) .
Our hypothesis was that this difference might be attributed to the fraction subset of patients that had the worst prognosis at baseline. Therefore, we decided to look at patients with TN and the HER2 positive tumours specifically.
The comparator groups were well balanced with tumour size at baseline in the TN cohort being the only significant difference. This difference seems to be irrelevant because tumour size on its own has no effect on survival when lymph node status is similar especially in patients with TN tumours (17) .
Both cohorts received the same chemotherapy schedules and in the HER2-positive cohort the same amount of trastuzumab. They achieved similar proportions of pathological complete response. Endocrine therapies according to menopausal status were the same for both groups. However, even though these were consecutive patients, a selection bias cannot be excluded because this was not a randomised trial.
In the TARGIT-A study (1) there was a trend for superior overall survival with TARGIT-IORT compared with EBRT and this was mainly attributable to reduced mortality from causes other than breast cancer. It has also been suggested that the favourable effects of IORT on surgical wound fluid may result in wider systemic beneficial effects that may have contributed to the reduced mortality seen in the TARGIT-A trial.
A non-randomised comparison of those patients in the TARGIT-A trial who received IORT + EBRT versus those who received EBRT found a statistically significant reduction in non-breast-cancer mortality. There were no deaths from non-breast cancer causes in the IORT+EBRT group compared with 24 in the EBRT group 0/218 vs 24/892, log-rank p = 0.012. (18) . An explanation that the authors suggested for this phenomenon was a potential influence of immediate IORT on local tumour microenvironment and wound fluid that could get absorbed and cause systemic beneficial effects. Laboratory experiments using tumour cells lines have shown that would fluid after lumpectomy stimulates breast cancer cell proliferation, motility and invasiveness, an effect that is abrogated if the patient receives IORT during the lumpectomy (19) . It has also previously been discussed that IORT during lumpectomy may be changing the systemic course of not just breast cancer but also that of other fatal diseases, for the better (20) .
The clinical data reported from our group before (11) seem to support the hypothesis that the benefit of IORT may not be limited to avoiding a geographic and temporal miss. But due to the retrospective character of our trial we are recommending a cautious interpretation of these data. In the analysis presented in this paper including only the triple negative and HER2 positive cases we could not reproduce the significant overall survival benefit shown for the use of TARGIT-IORT as a boost after neoadjuvant chemotherapy in the whole cohort. The reason for this may be the small number of events, but it may also indicate that the results for the whole cohort were mainly attributable to the subset of patients with hormone receptor positive and HER2 negative tumours. However, trends for DFS and OS were favourable for TARGIT-IORT in the present analysis. Therefore we believe that using TARGIT-IORT as a tumour bed boost after neo-adjuvant chemotherapy is unlikely to be detrimental.
The hypothesis of a possibility of systemic beneficial effects of IORT will be prospectively tested in the TARGIT-B international randomised trial comparing TARGIT Boost vs. EBRT Boost in women who are either younger than 45 or have a higher risk of local recurrence, including those who have received neoadjuvant chemotherapy. We encourage active participation in this trial.
shown and the significantly positive result for overall survival in the whole cohort of 116 patients could not be reproduced in this subset analysis of patients with TN and HER2 positive tumours. The reason for this may be the small number of events, but it may also indicate that the results for the whole cohort were mainly attributable to the subset of patients with hormone receptor positive and HER2 negative tumours.
The non-inferiority of TARGIT-IORT as an intraoperative boost could be reproduced in these high-risk patients.
